/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
With a market cap of $9.4 billion, Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) is a leading contract research organization (CRO) in the healthcare sector. It offers a wide range of services, including research models, safety assessments, and manufacturing support to facilitate drug development for pharmaceutical and biotechnology clients globally. CRL is expected to release its fiscal Q3 earnings results before the market opens on Wednesday, Nov. 6.
Ahead of this event, analysts expect the contract drug developer to report a profit of $2.43 per share, down 10.7% from $2.72 per share in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the last four quarters. CRL exceeded the consensus EPS estimate by 17.2% in the most recent quarter.